|Full Disclosure Policy Affecting CE Activities
As a sponsor accredited by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:
L. Brian Cross, PharmD, CDE
University of Tennessee Health Science Center
Colleges of Pharmacy and Medicine
Co-Director, Department of Disease Management
Holston Medical Group
• Dr Cross reports serving as a consultant for AstraZeneca, Pfizer, Inc, and Sanofi-Aventis; and receiving honoraria from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, and Pfizer, Inc.
Stephen N. Davis, MD, FRCP
Chief, Division of Diabetes, Endocrinology, and Metabolism
Mark Collie Professor
Medicine and Molecular Physiology and Biophysics
Vanderbilt University School of Medicine
• Dr Davis reports receiving grants/research support from Bayer Corporation, Eli Lilly and Company, King Pharmaceuticals, and Sanofi-Aventis.
Jean-Venable R. Goode, PharmD, BCPS, FAPhA
Department of Pharmacy
Director, Community Pharmacy Practice Program
Virginia Commonwealth University
• Dr Goode reports having no significant financial or advisory relationships with corporate organizations related to this activity.
Notice: In accordance with ACPE Criteria for Quality, the audience is advised that the articles in this CE activity contain no reference(s) to unlabeled or unapproved uses of drugs or devices.
University of Tennessee Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. University of Tennessee Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.